The present invention relates to the field of medicine, generally to the field of surgical and emergency medical wound covering means on the base of haemostatic composition designated as Hemoblok. The invention proposes a new method of usage of these haemostatic compositions to activate the formation of artificial clots that can adhere to wounded tissue for the suppression of fluid loss and for the protection of viable tissue. The method consists of the steps to be applied to the open wound a grid-forming water-soluble haemostatic Hemoblok composition consisting of a polyacrylic matrix as an active ingredients, creating by Hemoblok the clot formation with the blood plasma proteins, preferably with albumin, creating a structure containing albumin molecules in the cells of the polyacrylic matrix (grid), which is the primary organizer of sustainable polyacrylic film, further forming by Hemoblok the multilayered solid polyacrylic film, then the replacement by fibrin of the surface structure hemoblok-protein and implementation of plasma formation of the polyacrylic matrix. Another object of the invention is a kit for creation of wound covering, comprising, packaged in association a Hemoblok composition, and a dispenser for applying the Hemoblok to open wounds, which is made as a woven or a non-woven fabric, a tube, a bandage or a container having at least one opening.

A wound dressing having a chromic material responsive to at least one stimuli. In one or more embodiments, a plurality of individual liquid expandable articles introduce the chromatic material to the wound. The individual liquid-expandable articles release stored mechanical energy and mechanically expand into expanded articles upon contact with a liquid associated with the wound. In response to the chromic material receiving the at least one stimuli the chromic material provides a color change evidencing how long the expanded articles have been in contact with the wound and where the expanded articles are within the wound. In one or more embodiments, determinations may be made about removing the expanded articles from the wound based on the color of the chromic material.

A method for obtaining a biopolymer hemostatic powder including adding in an reactor (1) a mixture of an organic acid (b), a combination of alcohols (b) (d) and a bioadhesive to obtain a binder solution and a step of incorporating on a base of the lower part of a fluid bed reactor (2) a polysaccharide (a) driven by an air stream injected at controlled temperature and speed; on which fluid and micro particles of the polysaccharide (a) are sprayed from the top of said fluid bed reactor (2) the binding solution and where the polysaccharide (a) is chitosan, the organic acid (b) is acetic acid, the alcohol combination (c) is alcohol and polyalcohol and the bioadhesive is polyvinyl alcohol. The product contains between 55 and 85% w/w of a polysaccharide; between 10 to 40% w/w of an organic acid; up to 17% w/w of a combination of alcohols and up to 3% w/w of a bioadhesive; whose alcohol combination is composed of 95% of an alcohol and 5% of a polyalcohol and the binder fluid is sprayed onto the polymer in an amount of between 50 and 150% p/p.

The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyimide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.

A bioresorbable haemostatic foam sponge for adhering to a wound. The sponge has a tissue-contacting surface divided into a plurality of closely-spaced tissue contacting elements. Also disclosed are methods for forming the haemostatic sponge and methods of using the sponge.

The disclosed invention is a device and method of use for gauze utilized in the treatment of hemorrhage. In an embodiment the device combines clotting factor concentrator gauze and urea in order to slow hemorrhage and prevent hemorrhage induced coagulopathy. In an embodiment, the gauze is comprised of a first layer comprised of gauze and a second layer embedded with urea. The urea reacts spontaneously when it comes into contact with water, and undergoes an endothermic reaction. This endothermic reaction cools the smaller blood vessels exposed from soft tissue trauma, causing enhanced platelet activity as well as vasoconstriction to minimize the bleeding that occurs before and after the clotting cascade is activated over the entire wound surface.

Methods, materials, articles, assemblies, systems, devices, kits and computer hardware/software for improving medical procedures, including, but not limited to, hemodialysis. Particular beneficial designs and uses of disinfecting patches, scab removal patches, hemostatic patches, healing patches and artificial scabs are included. For example, scab removal patches that avoid tenting, hemostatic patches with needle stabilizing elements, hemostatic patches applying pressure at a skin puncture site and a vessel puncture site, artificial scabs that release antimicrobial agents, etc.

A hemostatic surface application device having a region of hemostatic foam for contact with a patient's skin where a wound exists or is created, the device includes: a release layer, the release layer in contact with a hemostatic flexible foam section, and a structural foam layer having a front side and a back side surrounding the hemostatic flexible foam layer, forming a generally central hemostatic surface exposed through the front side of the surrounding structural foam layer, and a support layer adhered to the backside of the structural foam layer.

A knit hemostatic bandage provided herein can include a continuous rayon fiber and a continuous glass fiber. The knit hemostatic bandage can have a gauge of between 10 and 30 stitches per inch. The knit hemostatic bandage can have a Young's modulus of elasticity of less than 50 MPa.

The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.